ACE2-Fc fusion protein function test method for treating COVID-19

Abstract

The invention provides an ACE2-Fcfusion protein function test method for treating COVEID-19. The ACE2-Fc fusion protein function test method specifically comprises the following steps of expressing ahuman wild type ACE2-Fc fusion protein: cloning a DNA sequence of an extracellular domain (ECD) of human wild type ACE; enabling the ECD of the ACE2 to be fused with the Fc part of the human IgG1, sothat the half-life period of the soluble ACE2 is prolonged; expressing the ACE2-Fc fusion protein in CHO cells, and purifying the ACE2-Fc fusion protein in a cell culture supernatant by using proteinA / G agarose; and optimized an expression system. The invention effectively proves that the ACE2-Fc fusion protein can prevent or block viruses from entering cells, slow down the infection process andexpose the viruses to the outside of the cells so as to be recognized and eliminated by a human immune system.

Description

technical field

[0001] The invention relates to the technical field of fusion proteins, in particular to a method for testing the function of ACE2-Fc fusion proteins for treating COVID-19. Background technique

[0002] The coronavirus first binds to the target receptor on the surface of the host cell through protein spikes, and after fusion with the cell membrane, the viral nucleocapsid enters the cell for subsequent replication. In SARS-CoV cases, the spike protein on the surface of the virion mediates receptor recognition and membrane fusion. During viral infection, the trimeric S protein is cleaved into S1 and S2 subunits, and the S1 subunit is released during the transition to the postfusion conformation. S1 contains the receptor-binding domain (RBD), which directly binds to the peptidase domain (PD) of ACE2, while S2 is responsible for membrane fusion. Given the high sequence homology (70–80%) between SARS-CoV-2 and SARS-CoV, it has recently been shown that the extrac...

Images